A multicentre, randomized, double masked, 4-p...
RESEARCHER: Dr. Jesús Merayo Lloves ACTIVO A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety
“Double-blind, placebo-controlled phase...
RESEARCHER: Dr. Jesús Merayo Lloves RECLUTANDO "Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye" INDICATION: Pacientes con ojo seco leve o moderado TREATMENT: AVX-012 PROMOTOR: Avizorex Pharma
A dose-Ranging, Muti-Centre, Randmised, Doubl...
RESEARCHER: Prof. Luis Fernández-Vega Sanz RECLUTANDO A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD) INDICATION: Pacientes con degeneración macular
Phase IV, randomized, double-blind, simulated...
RESEARCHER: Dr. Álvaro Fernández-Vega Sanz ACTIVO Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC) INDICATION: Patients with polypoid choroidal vasculopathy TREATMENT: Aflibercept PROMOTOR: AIBILI
Macular edema secondary to occlusion of the c...
RESEARCHER: Dr. Álvaro Fernández-Vega Sanz RECLUTANDO INDICATION: Macular edema secondary to occlusion of the central TREATMENT: Aflibercept PROMOTOR: Bayer AG
Double masked SYL1001 study in patients with ...
RESEARCHER: Dr. Jesús Merayo Lloves RECLUTANDO Double masked SYL1001 study in patients with moderate or severe dry eye disease INDICATION: Patients with moderate to severe dry eye TREATMENT: SYL1001 PROMOTOR: SYLENTIS